Integrated delivery device for continuous glucose sensor
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.
1. A diabetes management system for semi-automated integration of a continuous glucose sensor and a medicament delivery device to maintain a host's glucose levels within a desired target range, the system comprising:
a continuous glucose sensor configured to continuously measure glucose in a host and to output a data stream including one or more sensor data points;
a processor module operably connected to the continuous glucose sensor, wherein the processor module is configured to receive the data stream, evaluate a clinical risk, determine whether to operate in either a first mode or a second mode based on whether the clinical risk meets one or more predetermined criteria, and send therapy instructions to a medicament delivery device in the first mode but not in the second mode; and
a medicament delivery device operably connected to the processor module and configured to receive and execute the therapy instructions.
2. The diabetes management system of claim 1 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on a glucose concentration value of the host measured by the continuous glucose sensor.
3. The diabetes management system of claim 1 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on a rate of change of the glucose concentration of the host measured by the continuous glucose sensor.
4. The diabetes management system of claim 1 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on an acceleration of the glucose concentration of the host measured by the continuous glucose sensor.
5. The diabetes management system of claim 1 , wherein the clinical risk is determined based on an evaluation of a glucose value measured by a single point glucose monitor.
6. A method for calculating and sending therapy instructions to a medicament delivery device to maintain a host's glucose levels within a desired target range, the method comprising:
generating a data stream from a substantially continuous glucose sensor, the data stream including one or more sensor data points;
receiving the data stream, by a processor module;
detecting, by the processor module, a clinical risk; and
calculating, by the processor module, instructions for administration of a medicament by a medicament delivery device; and
determining, by the processor module, whether to send the instructions for administration of the medicament to the medicament delivery device based on whether the clinical risk meets a predetermined criterion; and
sending the instructions to the medicament delivery device based on the determination.
7. The method of claim 6 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on a measured or estimated glucose concentration value of the host.
8. The method of claim 6 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on a measured or estimated rate of change of the glucose concentration of the host.
9. The method of claim 6 , wherein the clinical risk is an identified danger or potential risk to the health of the host based on an estimated or measured acceleration of the glucose concentration of the host.
10. The method of claim 6 , wherein the clinical risk is determined based on clinical acceptability evaluation of a discrepancy between a glucose value measured by a single point glucose monitor and the one or more sensor data points of the continuous glucose sensor that could cause a risk to the patient if incorrect therapy is administered.
11. An integrated diabetes management system comprising a non-transitory computer readable medium stored in memory that is configured to cause a processor to receive a data stream from a substantially continuous glucose sensor, the data stream including one or more sensor data points, calculate a therapy comprising instructions for administration of a medicament, and automatically send the instructions to a medicament delivery device in a fully-automated mode unless a semi-automated mode is triggered, wherein the fully automated mode does not require user interaction to send instructions to the medicament delivery device, wherein the semi-automated mode requires user interaction before sending instructions to the medicament delivery device, and wherein the semi-automated mode is triggered responsive to detection of a clinical risk.